HM17321 / Hanmi - LARVOL DELTA

A Novel UCN2 Analog HM17321 with HM15275 Improves Body Composition in Mouse Model of Obesity (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Preclinical • Metabolic Disorders • Obesity

A Novel CRFR2 Selective UCN2 Analog, HM17321, Facilitates Weight Loss and Improves Body Composition across Animal Models of Obesity (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Preclinical • Metabolic Disorders • Obesity

A Novel CRFR2-Selective UCN2 Analog, HM17321, Improves Glycemic Control across Multiple Preclinical Models (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Preclinical • Metabolic Disorders

[Report Briefing] Hanmi Pharmaceutical, 'Momentum recovery expected in the second half' Target price 330,000 won - Kiwoom Securities [Google translation] (Nate) - "'The 1Q25 performance is expected to fall slightly short of market expectations. The presentation of the phase 1 trial of HM15275 (LA-GLP/GIP/GCG) and the preclinical study results of HM17321 (LA-UCN2) are scheduled for the American Diabetes Association (ADA) in June.'"

P1 data • Preclinical • Obesity

Wegovy dominates, but local challengers emerge (Korea Biomedical Review) - "Novo’s ambitions in Korea are perhaps clearest in the obesity market, where GLP-1 drug Wegovy (semaglutide) is already seeing breakout demand. Sales hit 8.87 billion won ($6.19 million) in the first two months of 2025—nearly half its 2024 full-year total of 18.46 billion won....A triple agonist, HM15275, is entering phase 2 in the second half of this year, while HM17321, designed to preserve muscle mass during weight loss, is slated for phase 1 in 2026."

New P1 trial • New P2 trial • Sales • Obesity

'Korean-style obesity drug' to be launched next year···Hanmi Pharmaceuticals to conduct phase 3 new drug trial [Google translation] (Nate) - "According to industry sources on the 4th, Hanmi Pharmaceutical plans to commercialize its obesity drug candidate 'Efpeglenatide', which is currently undergoing domestic phase 3 clinical trials, by the second half of 2026. This is about half a year earlier than the original target date of the first half of 2027....In addition, 'HM17321', which shows a weight loss effect similar to Wegovy and Mounjaro while also increasing muscle, is scheduled to enter phase 1 clinical trials in the second half of this year."

Launch • New P1 trial • Obesity

Hanmi Pharmaceutical's 'Obesity Drug' Expected to Transfer Technology Overseas... Aiming for a Rebound [Google translation] (Money Today) - "According to the industry, Hanmi Pharmaceutical is expected to disclose the US phase 1 clinical data of 'HM15275' (LA-TRIA), a triple agonist for obesity treatment...at the American Diabetes Association (ADA) in June. The preclinical data of 'HM17321' (LA-UCN2), another major pipeline of the company, is also expected to be presented at the conference....It has been reported that Hanmi Pharmaceutical held meetings with overseas pharmaceutical companies regarding HM15275 and HM17321 during the 'JP Morgan Healthcare Conference' held last month. As overseas competing products have minimal weight loss effects compared to muscle gain effects, there are high expectations that active discussions on technology transfer for both monotherapy and combination therapies in Hanmi Pharmaceutical's pipeline will continue."

Commercial • P1 data • Preclinical • Obesity